New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity.

Area of Science:

• Endocrinology and Metabolism
• Pediatric Obesity Research
• Pharmacology

Background:

• Rising global rates of childhood obesity pose significant future health risks.
• Current obesity treatments have limited long-term efficacy and potential side effects.
• Weight regain is a common challenge following weight loss interventions.

Purpose of the Study:

• To systematically review the therapeutic potential of Glucagon-like peptide-1 receptor agonists in pediatric obesity.
• To evaluate the efficacy and safety of these agents in managing weight and related metabolic factors in children.
• To explore novel treatment strategies for pediatric obesity by understanding the incretin axis.

Main Methods:

• Systematic review of clinical trials in pediatric populations up to 2025.
• Searched ClinicalTrials.gov database using "Glucagon like peptide-1 analog, Glucagon like peptide-1 receptor agonists" as intervention.
• Evaluated entero-insular axis, mechanisms of action, and therapeutic potential of GLP-1 receptor agonists.

Main Results:

• Glucagon-like peptide-1 receptor agonists target multiple pathways involved in weight regulation.
• Analysis included incretin hormones and FDA-approved medications.
• Evidence suggests potential for these agonists in pediatric weight management.

Conclusions:

• Glucagon-like peptide-1 receptor agonists represent a promising therapeutic avenue for pediatric obesity.
• Further research is needed to optimize long-term use and address weight regain.
• Understanding the incretin axis is crucial for developing effective obesity treatments.